Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | BCR | P11274 | 3/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.31 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776033 | 0.83 | FGFR4 (0.42) | CNR1ABL1BCRMAP4K1SMN1; SMN2 | |
| SCHEMBL16776216 | 0.82 | ABL1 (0.34) | ABL1MAP4K1 | |
| SCHEMBL16776122 | 0.82 | TP53 (0.36) | CNR1ABL1BCRMAP4K1SMN1; SMN2 | |
| SCHEMBL16776204 | 0.81 | DYRK1A (0.34) | ABL1 | |
| SCHEMBL16776040 | 0.80 | FGFR4 (0.41) | CNR1ABL1BCRFYNHSD17B14 | |
| SCHEMBL16776144 | 0.75 | KMT2A (0.44) | CNR1SMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL16775960 | 0.74 | DYRK1A (0.36) | FYN | |
| SCHEMBL16776146 | 0.73 | HTR2C (0.48) | ABL1BCRALDH1A1 | |
| SCHEMBL16776157 | 0.71 | ROCK2 (0.36) | ABL1BCRRPS6KA2TRPV1 | |
| SCHEMBL16776392 | 0.71 | SLC5A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CNR1 2946/4885ABL1 4089/4885BCR 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.